Management of Severe Hyperkalemia
For severe hyperkalemia with ECG changes, muscle weakness, and impaired renal function, immediately administer IV calcium gluconate (15-30 mL of 10% solution over 2-5 minutes) to stabilize the cardiac membrane, followed simultaneously by insulin (10 units regular IV) with glucose (25g) and nebulized albuterol (10-20 mg) to shift potassium intracellularly, then arrange urgent hemodialysis as the definitive treatment for potassium removal in the setting of renal failure. 1, 2
Immediate Emergency Treatment (First 15 Minutes)
Step 1: Cardiac Membrane Stabilization (Acts in 1-3 minutes)
- Administer IV calcium first before any other intervention if ECG changes are present 1, 2, 3
- Calcium gluconate (10%): 15-30 mL IV over 2-5 minutes OR calcium chloride (10%): 5-10 mL IV over 2-5 minutes 1, 2
- Effects begin within 1-3 minutes but last only 30-60 minutes 2, 3
- Critical caveat: Calcium does NOT lower serum potassium—it only temporarily stabilizes cardiac membranes 2, 3
- If no ECG improvement within 5-10 minutes, repeat the same dose 2, 3
- Continuous cardiac monitoring is mandatory during administration 2, 3
Step 2: Shift Potassium Intracellularly (Acts in 15-30 minutes)
Give all three agents together for maximum additive effect: 1, 2
Insulin + Glucose: 10 units regular insulin IV with 25g glucose (50 mL of D50) over 15-30 minutes 1, 2
Nebulized Albuterol: 10-20 mg in 4 mL nebulized over 15 minutes 1, 2
Sodium Bicarbonate: 50 mEq IV over 5 minutes ONLY if metabolic acidosis is present (pH <7.35, bicarbonate <22 mEq/L) 1, 2
Definitive Potassium Removal
For Patients with Impaired Renal Function:
Hemodialysis is the most effective and reliable method for severe hyperkalemia, especially with renal failure 1, 2, 4
- Arrange urgent dialysis immediately after stabilization measures 2, 4
- This is the only definitive treatment that removes potassium from the body in renal failure 2
For Patients with Adequate Renal Function:
- Loop diuretics: Furosemide 40-80 mg IV to increase urinary potassium excretion 1, 2
- Only effective if eGFR allows adequate urine output 2
Potassium Binders (Adjunctive, Not Acute):
- Sodium polystyrene sulfonate (Kayexalate): 15-50g plus sorbitol per oral or per rectum 1
- Newer agents (patiromer, sodium zirconium cyclosilicate) are preferred for chronic management but not for acute emergencies 2
Medication Management During Acute Episode
Immediately review and temporarily discontinue: 2
- RAAS inhibitors (ACE inhibitors, ARBs, mineralocorticoid antagonists) if K+ >6.5 mEq/L 2
- Potassium-sparing diuretics (spironolactone, amiloride, triamterene) 2
- NSAIDs 2
- Trimethoprim 2
- Heparin 2
- Beta-blockers 2
- Potassium supplements and salt substitutes 2
Monitoring Protocol
- Continuous cardiac monitoring throughout acute treatment 2, 3
- Recheck serum potassium every 2-4 hours after initial interventions 2
- Monitor blood glucose closely after insulin administration 2, 3
- Obtain repeat ECG after calcium administration to document improvement 3
Critical Pitfalls to Avoid
Never delay calcium administration while waiting for repeat lab confirmation if ECG changes are present—ECG changes indicate urgent need regardless of exact potassium value 2, 3
Never give insulin without glucose—hypoglycemia can be life-threatening 2
Never use sodium bicarbonate without documented metabolic acidosis—it is ineffective and delays appropriate treatment 2
Never rely on calcium, insulin, or albuterol alone—these are temporizing measures that do NOT remove potassium from the body 2
Never administer calcium through the same IV line as sodium bicarbonate—precipitation will occur 2
Do not rule out pseudohyperkalemia from hemolysis, repeated fist clenching, or poor phlebotomy technique, but do not delay treatment if clinical suspicion is high 2, 3
Post-Acute Management
Once potassium <5.5 mEq/L: 2
- Initiate newer potassium binder (patiromer or sodium zirconium cyclosilicate) 2
- Restart RAAS inhibitors at lower dose if indicated for cardiovascular or renal disease 2
- These medications provide mortality benefit and should not be permanently discontinued 2
- Arrange close follow-up with potassium monitoring within 1 week 2